Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy - Tu, Hai‐Yan; Yin, Kai; Zhao, Xiaotian; Ke, E‐E; Wu, Si‐Pei; Li, Yang‐Si; Zheng, Mei‐Mei; Liu, Si‐Yang Maggie; Xu, Chong‐Rui; Sun, Yue‐Li; Lin, Jia‐Xin; Bai, Xiao‐Yan; et al. (Molecular oncology, 2023)
Keywords: advanced NSCLC; Apoptosis; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Committees; Epidermal growth factor; ErbB-2 protein; exon 20 insertion; FDA approval; Genes; Genomes; Genomics; human epidermal growth factor receptor 2; Humans; immune checkpoint inhibitor; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Kinases; Leukocytes; Ligands; Lung Cancer; Lung diseases; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical prognosis; Mutation; Mutation - genetics; Non-small cell lung carcinoma; non‐exon 20 insertion; Patients; PD-L1 protein; Plasma; Retrospective Studies; Small cell lung carcinoma; Tumor Microenvironment; United States--US; immune checkpoint inhibitor; human epidermal growth factor receptor 2; advanced NSCLC; exon 20 insertion; non-exon 20 insertion